Veracyte (VCYT +5.3%) will collaborate with MAVIDx to develop high throughput genomic testing for SARS-CoV-2 on the nCounter Analysis System, Veracyte’s diagnostics platform. Financial terms are not disclosed.
The tests may enable processing of 40,000+ patient samples per day using molecular barcodes for viral RNA.
Veracyte has secured an equity stake in MAVIDx and will supply the company’s infectious disease test kits and nCounter instruments.
Veracyte acquired the exclusive global diagnostic rights to the nCounter system from NanoString in December 2019.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.